1
Archaebacteria but instead was a chimera formed by fusion and integration of the genomes of an archaebacterium and a gram-negative bacterium. The available data indicate that the primary fusion event that gave rise to the ancestral eukaryotic cell was unique and that it was very probably distinct from (and preceded) the one that gave rise to mitochondria and hydrogenosomes. These results provide e
3
Ell, T., and R. G. E. Murray. 1986. Polar lipid profiles of the genus Deinococcus. Int. J. Syst. Bacteriol. 36:202?06. 40. Craig, E. A. 1993. Chaperones: helpers along the pathways to protein folding. Science 260:1902?903. 41. Craig, E. A., B. D. Gambill, and R. J. Nelson. 1993. Heat shock proteins: molecular chaperones of protein biogenesis. Microbiol. Rev. 57:402?14. 42. Creti, R., E. Ceccarelli
1
Ell, T., and R. G. E. Murray. 1986. Polar lipid profiles of the genus Deinococcus. Int. J. Syst. Bacteriol. 36:202?06. 40. Craig, E. A. 1993. Chaperones: helpers along the pathways to protein folding. Science 260:1902?903. 41. Craig, E. A., B. D. Gambill, and R. J. Nelson. 1993. Heat shock proteins: molecular chaperones of protein biogenesis. Microbiol. Rev. 57:402?14. 42. Creti, R., E. Ceccarelli
1
Ch are urgently needed for the constant stream of newly reported putative serological biomarkers. For example, emerging proteomic techniques such as high density protein microarrays (Hudson et al., 2007; Babel et al., 2009; Anderson et al., 2011) have greatly accelerated the pace at which candidate TAAs are currently being discovered. However, a major bottleneck is the rigorous clinical validation
1
T or a cell-free produced p53 protein compared well to the ELISA data (96 "hit" concordance in CRC) confirming the validity of the method. Indeed, the only discordance occurred where the VeraCodeTM immunoassays were able to reproducibly detect two additional low-positive, statistically valid CRC hits (4 increase in diagnostic sensitivity). This increased sensitivity is likely the result of decre
1
D reported here is ideally suited both for clinical validation and diagnostic detection of serological biomarker panels or signatures, including autoantibodies against TAAs as well as non-antibody protein biomarkers.J Immunol Methods. Author manuscript; available in PMC 2014 December 31.Ostendorff et al.PageTechnical validation of the tumor biomarker assay itself is a critical step in the developm